Top pharma stock to watch: TD Cowen’s pick

TD Cowen identifies Kiniksa Pharmaceuticals (KNSA) as a top pick in the pharma sector, citing strong commercial momentum for Arcalyst and potential value from pipeline candidates. The firm set a $115 price target, noting underpenetrated markets and conservative revenue growth projections. KPL-387, a wholly owned drug, could add $6 to earnings per share by 2027.

Original reporting
Published Nov 18, 2026, 7:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 7:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$KNSA
Bullish
high confidence
Mentioned
$KNSA
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$KNSABullishMed
01

Why it matters

Analyst initiation and a $115 target could attract new capital, especially from biotech‑focused funds.

02

Market read

The coverage may trigger short‑term buying pressure in KNSA and modestly benefit peer biotech stocks.

03

What to watch

Potential regulatory delays for the pipeline and reliance on a single product line could temper upside.

Relevance 7/10Novelty 7/10Timing: immediate

Background

TD Cowen's new coverage of Kiniksa follows recent sales growth for Arcalyst and upcoming Phase III data for KPL-387.

Company-level read

Ticker impact

$KNSABullishHigh confidence
Context

TD Cowen initiates coverage of Kiniksa Pharmaceuticals with a $115 price target, citing growth potential for Arcalyst and pipeline candidate KPL-387.

Expected impact

upward pressure as investors price in the bullish outlook and pipeline upside.

Evidence & confidence

The report provides new valuation and growth assumptions not previously disclosed, which can move the stock in the short term.

Market effects

May lift sentiment for the broader pharmaceutical sector as analysts highlight under‑penetrated markets.

U.S. biotech and pharma equities could see modest gains.

Limited to investors focused on U.S. biotech; no broad macro effect.

Counterpoint

The price target may be overly optimistic given execution risk for KPL-387 and competition in IL‑1 antagonists.

Key entities

  • Kiniksa Pharmaceuticals

    U.S. biotech developing IL‑1 antagonists.

  • TD Cowen

    Equity research boutique issuing the coverage.

Related articles

$KNSAMedAI 8/10

Kiniksa Pharmaceuticals, Ltd. Q3 2026 Earnings Call Summary

Kiniksa Pharmaceuticals reported Q3 2026 revenue growth of 58% YoY, driven by increased market penetration and physician adoption of IL-1 inhibition. The company raised full-year revenue guidance to $1.045B-$1.050B. It plans to initiate a Phase I trial for KPL-1161 by year-end and expects KPL-387 Phase III data in H2 2027. Kiniksa ended the quarter with $568.8M in cash.

$KNSAHigh

Kiniksa (KNSA) Q3 2026 Earnings Call Transcript

Kiniksa reported Q3 2026 revenue of $286M for ARCALYST, up 58% YoY. The company expects KPL-387 trial data in 2H 2027 and aims for a 2028-2029 launch. ARCALYST penetration in recurrent pericarditis patients reached 23%. Kiniksa forecasts $1B+ in 2026 ARCALYST revenue and is investing in AI-driven patient identification and marketing campaigns. Operating income was $54.2M, net income $47.3M, with $568.8M in cash at quarter-end.